| Literature DB >> 31875053 |
Kuo-Lung Lor1, Cheng-Pei Liu1, Yeun-Chung Chang2, Chong-Jen Yu2, Cheng-Yi Wang3, Ming-Jui Chung1, Fan-Ya Lin1, Chung-Ming Chen4.
Abstract
Target lung tissue selection remains a challenging task to perform for treating severe emphysema with lung volume reduction (LVR). In order to target the treatment candidate, the percentage of low attenuation volume (LAV%) representing the proportion of emphysema volume to whole lung volume is measured using computed tomography (CT) images. Although LAV% have shown to have a correlation with lung function in patients with chronic obstructive pulmonary disease (COPD), similar measurements of LAV% in whole lung or lobes may have large variations in lung function due to emphysema heterogeneity. The functional information of regional emphysema destruction is required for supporting the choice of optimal target. The purpose of this study is to develop an emphysema heterogeneity descriptor for the three-dimensional emphysematous bullae according to the size variations of emphysematous density (ED) and their spatial distribution. The second purpose is to derive a predictive model of airflow limitation based on the regional emphysema heterogeneity. Deriving the bullous representation and grouping them into four scales in the upper and lower lobes, a predictive model is computed using the linear model fitting to estimate the severity of lung function. A total of 99 subjects, 87 patients with mild to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I~IV) and 12 control participants with normal lung functions (forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) > 0.7) were evaluated. The final model was trained with stratified cross-validation on randomly selected 75% of the dataset (n = 76) and tested on the remaining dataset (n = 23). The dispersed cases of LAV% inconsistent with their lung function outcome were evaluated, and the correlation study suggests that comparing to LAV of larger bullae, the widely spread smaller bullae with equivalent LAV has a larger impact on lung function. The testing dataset has the correlation of r = -0.76 (p < 0.01) between the whole lung LAV% and FEV1/FVC, whereas using two ED % of scales and location-dependent variables to predict the emphysema-associated FEV1/FVC, the results shows their correlation of 0.82 (p < 0.001) with clinical FEV1/FVC.Entities:
Mesh:
Year: 2019 PMID: 31875053 PMCID: PMC6930211 DOI: 10.1038/s41598-019-56351-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Box plot for each dataset showing both complete and training dataset have nearly normal distribution and equivalent interquartile range. All datasets have median line inside each other’s box.
Subject Demographics (n = 99).
| Parameter | Mean (±std) or count (%) |
|---|---|
| Sex male | 97 (97.97) |
| Age | 67.3 (12.94) |
| Height (cm) | 166.96 (6.77) |
| Weight (kg) | 67.22 (12.94) |
| FEV1/FVC % | 54.82 (12.74) |
| FEV1% predicted | 66.77 (22.28) |
| None | 12 (12.12) |
| GOLD stage I | 16 (16.16) |
| GOLD stage II | 48 (48.48) |
| GOLD stage III | 21 (21.21) |
| GOLD stage IV | 2 (2.02) |
Abbreviation: FEV1 – forced expiratory volume in one second, FVC – functional vital capacity, GOLD – the global imitative for chronic obstructive pulmonary disease.
Figure 2Data distributions among variables of complete dataset (n = 99).
Figure 4Data distributions among four categories of ED% in upper and lower lobes of complete dataset (n = 99).
Pearson’s r between LAV% and lung functions of complete dataset (n = 99).
| FEV1 (% pred.) | FEV1/FVC (%) | |
|---|---|---|
| Upper lobes | P < 0.001 −0.59 | P < 0.001 −0.60 |
| Lower lobes | P < 0.001 −0.61 | P < 0.001 −0.65 |
Whole lung | P < 0.001 −0.62 | P < 0.001 −0.66 |
Figure 5Scatter plot and linear regression of 99 subjects showing the relationship between lung function (FEV1/FVC% and FEV1% predicted) and LAV%.
Figure 6Emphysema heterogeneity with different representations for two cases (A,B). First column shows emphysematous density (ED) distribution of our approach. Second column shows voxel-wise density map. The third column shows low attenuation clusters (LACs) using commercial quantitative imaging software (Apollo; VIDA Diagnostics, Coralville, IA, USA).
The lung functions and LAV% of each case in Figure 6.
| Case | A. 2009102 | B. 2006102 |
|---|---|---|
| Whole lung LAV% | 14.74 | 1.56 |
| Upper lobes LAV% | 11.81 | 0.98 |
| Lower Lobes LAV% | 2.93 | 0.58 |
| FEV1/FVC% | 45.23 | 61.27 |
| FEV1% predicted | 55.88 | 69.37 |
| GOLD stage | 3 | 2 |
Figure 7Two cases, A and B have equivalent LAV%, but also have very different measurements in lung function.
Pearson’s r between Emphysematous Density (%) and FEV1/FVC (%) (n = 99).
| <5 mm | 5~20 mm | 20~50 mm | >50 mm | |
|---|---|---|---|---|
| Upper lobe | P < 0.001 −0.53 | P < 0.001 −0.51 | P < 0.001 −0.32 | P < 0.05 −0.22 |
| Lower lobe | P < 0.001 −0.58 | P < 0.001 −0.47 | P < 0.001 −0.37 | P = 0.1 −0.15 |
| Whole lung | P < 0.001 −0.58 | P < 0.001 −0.51 | P < 0.001 −0.36 | P < 0.05 −0.20 |
Abbreviation: ED- emphysematous density.
| Coefficient estimated (±std) (VIF) p-value | Model-A: Location dependent | Model-B: Size dependent | Model-C Both size and location dependent | Model-D Elaboration of Model-C |
|---|---|---|---|---|
| Intercept | 65.45 (1.58) P < 0.001 | 64.5 (1.56) P < 0.001 | 64.73 (1.58) P < 0.001 | 64.50 (1.58) P < 0.001 |
| ED -up | −0.32 (0.23) (3) P = 0.17 | |||
| ED -low | −0.82 (0.24) (3) P < 0.001 | |||
ED-all Small | −0.71 (0.10) (1) P < 0.001 | |||
ED-all Large | −0.43 (0.09) (1) P < 0.001 | |||
ED-low Small | −0.72 (0.39) (3) P < 0.1 | −0.720 (0.39) (3) P < 0.1 | ||
ED-low large | −0.88 (0.37) (4) P < 0.05 | −0.88 (0.37) (4) P < 0.05 | ||
ED-up Small | −0.71 (0.38) (3) P < 0.1 | −0.77 (0.38) (3) P < 0.05 | ||
ED-up Large | −0.02 (0.34) (4) P = 0.96 | |||
ED-up Size-2 | −0.09 (0.35) (3) P < 0.80 | |||
ED-up Size-3 | −0.52 (0.50) (1) P = 0.30 | |||
R-squared p-value | 0.43 P < 0.001 *** | 0.45 P < 0.001*** | 0.46 P < 0.001*** | 0.47 P < 0.001*** |
| AIC | 739.52 | 736.83 | 739.11 | 739.01 |
Simple linear regression model estimating outcome of FEV1/FVC % using complete dataset (n = 99).
ANOVA testing Model-C and Model-D: F-value is 1.99, p-value = 0.16.
Comparing the performance of predictive model between model C and D using training dataset; using linear regression model with 10-fold cross-validation repeated for 30 times.
| Coefficients estimated (±std) (VIF) p-value | Model-C Complete dataset (n = 76) | Model-D Training dataset (n = 76) |
|---|---|---|
| Intercept | 62.58 (1.80) P < 0.001 | 62.43 (1.82) P < 0.001 |
ED-low Small | −0.54 (0.43) P = 0.22 | −0.53 (0.44) P = 0.22 |
ED-low large | −0.87 (0.44) P < 0.05 | −0.85 (0.41) P < 0.05 |
ED-up small | −0.74 (0.41) P < 0.1 | −0.77 (0.42) P < 0.1 |
ED-up large | 0.00 (0.42) P < 0.99 | |
ED-up Size-2 | 0.06 (0.43) P = 0.89 | |
ED-up Size-3 | −0.24 (0.58) P = 0.68 | |
R-squared p-value | 0.44 P < 0.001 *** | 0.44 P < 0.001 *** |
| AIC | 570.24 | 571.80 |
| mean (±std) | ||
| RMSE | 9.72 (2.40) | 9.66 (2.33) |
| R-squared | 0.46 (0.21) | 0.47 (0.23) |
| MAE | 8.00 (1.99) | 8.04 (2.01) |
Final linear regression model estimating outcome of FEV1/FVC % n = 76.
Abbreviation: RMSE – root mean square error, MAE –mean absolute error.
Correlating with lung function, FEV1/FVC on testing dataset (n = 24).
| Predictor(s) | LAV % | Predicted by Model-C Both size and location dependent | Predicted by Model-D: Elaboration of Model-C |
|---|---|---|---|
| Pearson’s r | P < 0.001 −0.76 | P < 0.001 0.80 | P < 0.001 0.82 |
Figure 8Scatter plots and linear regression of showing the relationship between observed and estimated lung function, FEV1/FVC % in predictive model (C and D); and comparing the scatter plots of FEV1/FVC versus LAV% in testing dataset.
Figure 9Cases studies of dispersed cases inconsistent to measured FEV1/FVC%.